We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+13.19%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$12.1B
AUM Growth
+$1.25B
Cap. Flow
-$1.53B
Cap. Flow %
-12.71%
Top 10 Hldgs %
75.84%
Holding
141
New
6
Increased
25
Reduced
5
Closed
8

Top Buys

Rank Stock Value
1
ACOR
Acorda Therapeutics
ACOR
+$90.4M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$52.6M
3
DYAX
DYAX CORPORATION
DYAX
+$24.1M
4
ALKS icon
Alkermes
ALKS
+$17.5M
5
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$15.8M

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$18.6M
2
XNPT
XENOPORT, INC.
XNPT
+$17M
3
ALDR
Alder Biopharmaceuticals
ALDR
+$16.8M
4
RPRX
Repros Therapeutics Inc.
RPRX
+$14.5M
5
LRMR icon
Larimar Therapeutics
LRMR
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 78.52%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
1
Incyte
INCY
$25.9B
$2.11B 17.5%
19,475,316
+347
+0% +$38.7K
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$1.67B 13.87%
37,293,728
+1,263,982
+4% +$52.6M
ALXN
3
DELISTED
Alexion Pharmaceuticals
ALXN
$1.25B 10.34%
6,542,599
– –
ABBV icon
4
AbbVie
ABBV
$468B
$851M 7.05%
14,373,538
– –
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$5.08B
$730M 6.05%
20,481,442
– –
GHDX
6
DELISTED
Genomic Health, Inc.
GHDX
$481M 3.98%
13,659,264
+936
+0% +$25.1K
ANAC
7
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$474M 3.93%
4,198,520
+63,108
+2% +$6.95M
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$12.9B
$431M 3.57%
4,115,083
+38,730
+1% +$4.04M
DYAX
9
DELISTED
DYAX CORPORATION
DYAX
$313M 2.59%
8,310,017
+748,537
+10% +$24.1M
DBVT
10
DBV Technologies
DBVT
$914M
$198M 1.64%
546,202
– –
ACOR
11
DELISTED
Acorda Therapeutics
ACOR
$153M 1.27%
29,834
+20,693
+226% +$90.4M
BCRX icon
12
BioCryst Pharmaceuticals
BCRX
$2.44B
$147M 1.22%
14,217,779
+107,600
+0.8% +$1.07M
BLCM
13
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$98.6M 0.82%
486,565
+67,506
+16% +$12.1M
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$93.4M 0.77%
2,955,074
– –
CERS icon
15
Cerus
CERS
$566M
$85.7M 0.71%
13,553,275
– –
NGNE icon
16
Neurogene
NGNE
$773M
$84.2M 0.7%
337,367
– –
HRTX icon
17
Heron Therapeutics
HRTX
$60.4M
$77.6M 0.64%
2,907,784
– –
IMGN
18
DELISTED
Immunogen Inc
IMGN
$60.4M 0.5%
4,452,445
+904,405
+25% +$11.1M
ONCE
19
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$57.2M 0.47%
1,262,382
– –
NVTA
20
DELISTED
Invitae Corporation
NVTA
$53.8M 0.45%
6,554,967
– –
NBIX icon
21
Neurocrine Biosciences
NBIX
$15.5B
$48.1M 0.4%
850,739
+100,000
+13% +$5.08M
ARAV
22
DELISTED
Aravive, Inc. Common Stock
ARAV
$40.2M 0.33%
540,297
– –
SGMO
23
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$37M 0.31%
4,055,876
+300,000
+8% +$2.31M
HALO icon
24
Halozyme
HALO
$12.3B
$33.5M 0.28%
1,931,057
– –
ITCI
25
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$32.8M 0.27%
609,166
– –
1
2 3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q4 2015 Portfolio in Review

As of Q4 2015, Julian Baker held 141 positions worth $12.1B, up 12% from $10.8B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Julian Baker withdrew a net $1.53B in Q4 2015, closing 8 positions and reducing 5 holdings. Its most notable exit was Clovis Oncology, Inc., an estimated $18.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 78% a quarter earlier, followed by Technology.

Against the trend, Julian Baker opened a new position in Alkermes worth $19.9M.

  • Julian Baker's largest Q4 2015 buy was Alkermes: 250,251 shares worth $19.9M.
  • Julian Baker added most to Acorda Therapeutics in Q4 2015, an estimated $90.4M increase.
  • Julian Baker's biggest Q4 2015 reduction was XENOPORT, INC., cutting an estimated $17M.
  • Julian Baker fully exited Clovis Oncology, Inc. in Q4 2015, selling an estimated $18.6M.
  • Julian Baker's ten largest holdings make up 76% of its $12.1B portfolio in Q4 2015.
  • Julian Baker opened 6 new positions and closed 8 in Q4 2015.
  • Julian Baker's portfolio value rose 12% quarter-over-quarter to $12.1B.

Based on Baker Bros. Advisors's 13F filing for Q4 2015, filed 16 Feb 2016.